(Yicai Global) Oct. 12 -- Chief executives, top scientists and key investors from around the world have gathered in Shanghai for the city’s inaugural International Biopharma Industry Week to share their insights on edge-cutting trends and innovative achievements in the biopharmaceutical sectors.

Michael Levitt, 2013 Nobel Prize winner in chemistry, Zhang Boli, a medical expert who received the Chinese national accolade of People’s Hero due to his endeavors in the fight against Covid-19, Wang Xiaodong, co-founder of Chinese biotech startup BeiGene and Mark Leung, CEO of JP Morgan China are among the many luminaries who will give speeches.

With the theme of “Striving Together, Shaping Tomorrow,” representatives from the globe’s top biopharmaceutical companies will also offer their advice on transforming Shanghai into a world-class biomedicine industrial cluster during the week-long event from Oct. 11 to Oct. 14.

The biomedical sector, one of Shanghai’s leading industries, exceeded CNY600 billion (USD93 billion) in 2020. Shanghai plans to boost the industry’s value to CNY1.2 trillion (USD185.7 billion) by 2025, Wu Jincheng, director of the Shanghai Municipal Commission of Economy and Informatization, said earlier.

Zhang Boli, academician at the Chinese Academy of Engineering and honorary president of China Academy of Chinese Medical Sciences, delivers a speech.

Nobel-laureate Michael Levitt, professor of structural biology at Stanford University, takes the stage.

The Biopharma Cutting Edge Industry Innovation Center plaque is unveiled.

Partners of the World-class Biomedical Industry Cluster are announced. They include Shanghai Pharmaceuticals, Shanghai Fosun Pharmaceutical, Jiangsu Hengrui Medicine, the UK’s AstraZeneca, Switzerland’s Roche, France’s Sanofi, Chicago-based Arch Venture Partners and New York-based JP Morgan.

A roundtable discussion on the building of the industry cluster is held hosted by Jiang Ge, vice president of the Shanghai Tech University, with guests Xue Min, chairman of United Imaging Healthcare, Bian Xin, CEO of Roche China and Li Jia, director of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

Editors: Zhang Yushuo, Kim Taylor